Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing

Alzheon says it expects to fund the completion of a pivotal Phase III trial and regulatory filings later this year for its lead candidate, a treatment for early Alzheimer’s disease (AD), with proceeds from a $100 million Series E financing the company said it completed today.